Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
CUMBERLAND PHARMACEUTICALS INC
Bear Case (25th pct.)
-80.5% vs price
Base Case (Median)
-78.9% vs price
Bull Case (75th pct.)
-76.4% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $1.16 | -81.9% | High (40%) |
| EV/EBITDA | $1.67 | -74.0% | Medium (20%) |
| EV/FCF | $1.35 | -79.0% | Medium (20%) |
Based on 3 out of 7 methods, CPIX appears overvalued at the current price of $6.40. The base case fair value of $1.35 implies 78.9% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.